Get our Free Patent Expiration Newsletter

Serving hundreds of leading biopharmaceutical companies globally:

McKinsey
Daiichi Sankyo
Cipla
Covington
Chubb
Colorcon

Generated: September 23, 2019

DrugPatentWatch Database Preview

Patent: 7,320,961

  Try a free trial


See Plans and Pricing

« Back to Dashboard

Summary for Patent: 7,320,961
Title:Method for treating a disease, disorder or adverse effect caused by an elevated serum concentration of an UGT1A1 substrate
Abstract: The present invention is directed to a method for inducing UGT1A1 isoform expression for treatment of a disease, disorder or adverse effect caused by an elevated serum concentration of an UGT1A1 substrate comprising the step of administering to a subject an effective amount of ritonavir. In particular, the present invention is directed to a method of treating unconjugated hyperbilirubinemia by UGT1A1 induction comprising the step of administering to a subject an effective amount of ritonavir.
Inventor(s): Kempf; Dale J. (Libertyville, IL), Bertz; Richard J. (Kenosha, WI), Waring; Jeffrey F. (Franklin, WI)
Assignee: Abbott Laboratories (Abbott Park, IL)
Application Number:10/802,829
Patent Claims:see list of patent claims

Details for Patent 7,320,961

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Chiron PROLEUKIN aldesleukin VIAL 103293 001 1992-05-05 ➤ Sign Up Abbott Laboratories (Abbott Park, IL) 2023-03-24 RX search
Berlex Labs LEUKINE sargramostim VIAL 103362 001 1991-03-05 ➤ Sign Up Abbott Laboratories (Abbott Park, IL) 2023-03-24 RX search
Berlex Labs LEUKINE sargramostim VIAL 103362 002 1991-03-05 ➤ Sign Up Abbott Laboratories (Abbott Park, IL) 2023-03-24 RX search
Bayer Healthcare Pharms BETASERON interferon beta-1b VIAL; SUBCUTANEOUS 103471 001 1993-07-23 ➤ Sign Up Abbott Laboratories (Abbott Park, IL) 2023-03-24 RX Orphan search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Healthtrust
Merck
McKesson
Daiichi Sankyo
Federal Trade Commission
Argus Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.